Luliconazole Cream is indicated for the topical treatment of cutaneous mycosis, i.e. tinea pedis, tinea cruris, and tinea corporis in patients 18 years of age and older.
Luliconazole inhibits ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.
Interdigital Tinea Pedis: L-trix Cream, 1% should be applied to the affected and immediate surrounding area(s) once a day for 2 weeks. Tinea Cruris and Tinea Corporis: L-trix cream, 1% should be applied to the affected skin and immediate surrounding area(s) once a day for 1 week.
Hypersensitivity to luliconazole or any of the excipients of the formulation
In patients with hypersensitivity to luliconazole or any of the excipients of the formulation.
There are no available data with luliconazole cream, 1% use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. No information is available about the presence of the drug in human milk. The safety and effectiveness of luliconazole cream, 1% in pediatric patients 12 to<18 years of age with tinea pedis and tinea cruris have been established by evidence by well-controlled trials. The safety and effectiveness of luliconazole Cream, 1% in pediatric patients 2 to< 18 years with tinea corporis have been established by evidence from a well-controlled trial in pediatric subjects.
The potential of luliconazole to inhibit cytochrome P-450 (CYP) enzymes luliconazole at therapeutic doses, particularly when applied to patients with moderate to severe tinea cruris, may inhibit the activity of CYP2C19 and CYP3A4.
Common adverse reaction is application site reactions.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS